Johnson & Johnson $JNJ Shares Bought by 1900 Wealth Management LLC

1900 Wealth Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 45.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,219 shares of the company’s stock after purchasing an additional 2,574 shares during the period. 1900 Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,701,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Aspiriant LLC raised its position in Johnson & Johnson by 3.0% in the 4th quarter. Aspiriant LLC now owns 19,866 shares of the company’s stock valued at $4,111,000 after purchasing an additional 570 shares in the last quarter. Investment Planning Advisors Inc. acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $251,000. Cooksen Wealth LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $255,000. ASL Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $267,000. Finally, Wealth Management Associates Inc. raised its position in Johnson & Johnson by 0.8% in the 4th quarter. Wealth Management Associates Inc. now owns 10,300 shares of the company’s stock valued at $2,131,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Barclays increased their price target on Johnson & Johnson from $217.00 to $234.00 and gave the company an “equal weight” rating in a research report on Thursday, March 19th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. Stifel Nicolaus boosted their target price on Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. The Goldman Sachs Group restated a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, Leerink Partners boosted their target price on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $236.91.

Johnson & Johnson Trading Down 0.9%

JNJ opened at $240.87 on Tuesday. The firm has a market cap of $580.15 billion, a price-to-earnings ratio of 21.80, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71. The business’s 50 day moving average is $240.25 and its two-hundred day moving average is $213.73. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.